




I want to make the most of my time

With the exception of hemoptysis

In RELAY, adding CYRAMZA to erlotinib did not have a significant impact on overall QoL or average symptom burden¹⁴

Time to deterioration for LCSS: ITT population¹⁴



- Worsening in TTD for hemoptysis was consistent with symptoms expected in NSCLC and the known bleeding risk with CYRAMZA¹⁴
- CYRAMZA + erlotinib did not lead to a detriment in ECOG PS; however, there were insufficient events to perform a meaningful statistical evaluation. The exploratory analysis of TTD in ECOG PS revealed no difference between treatment arms¹⁴
- No significant differences were observed in the total LCSS score or in most individual symptom items¹⁴